Revolution Medicines Says FDA Granted Breakthrough Therapy Designation To RASONQUE In Combination With Gemcitabine And Nab-Paclitaxel For Treatment-Naive Metastatic Pancreatic Adenocarcinoma

뉴스 본문을 불러오고 있어요.

Revolution Medicines Says FDA Granted Breakthrough Therapy Designation To RASONQUE In Combination With Gemcitabine And Nab-Paclitaxel For Treatment-Naive Metastatic Pancreatic Adenocarcinoma | 웨이프 WAPE

Revolution Medicines Says FDA Granted Breakthrough Therapy Designation To RASONQUE In Combination With Gemcitabine And Nab-Paclitaxel For Treatment-Naive Metastatic Pancreatic Adenocarcinoma

기사 요약

관련 종목

댓글 —